Investor Presentaiton

13 Quick Response - Product Portfolio Against COVID-19 Covid-19 | Antiviral Treatment Azvudine Entered into a strategic collaboration with Genuine Biotech to develop and exclusively commercialize Azvudine, the first domestic small molecule anti Covid-19 oral drugs Obtained emergency conditional approval from NMPA to treat adult patients suffering moderate Covid-19 on July 25th Included in the Covid-19 prevention and control protocal (9th edition); included in the medical insurance in Gansu, Henan, Hainan and other provinces and cities; priced at RMB 270 for a course of treatment Collaborated with Sinopharm to supply Azvudine in China. Azvudine has been delivered to Henan, Hainan and Xinjiang to fight against the Covid-19 pandemic Sublicensed from MPP Sublicensed from MPP to manufacture drug substance and drug Molnupiravir from MSD and to commercialize in 105 low-and middle-income countries Sublicensed from MPP to manufacture drug substance and drug Nirmatrelvir from Pfizer and to commercialize drug substance and Paxlovid from Pfizer (Nirmatrelvir tablets and Ritonavir tablets) in 95 low-and-middle income countries • Others Entered into a license agreement with Kintor Pharma to commercialize Proxalutamide in India and 28 African countries Product pipeline includes long-acting fusion protein | drugs and bispecific nano-antibodies Covid-19 Diagnostic Test Kit & Biomedlab I COVID-19 nucleic acid test kit Received certifications from NMPA, CE, FDA, EUA, WHO EUL, TGA, etc., suppling to more than 10 countries and regions worldwide Covid-19 Vaccine mRNA Covid-19 Vaccine COVID 19 Antigen Test Kit Received certification from NMPA, CE; completed the German BfArM registration; included in the EU COVID 19 Rapid Antigen Tests Common List; received FDA Emergency Use Authorization Collaborated with BioNTech to develop and market mRNA COVID-19 vaccine in China (including Hong Kong, Macau and Taiwan region) Included in the COVID-19 vaccination programmes in Hong Kong and Macau region in March 2021 and was vaccinated in Taiwan region started in September 2021. Vaccine sales over 30 million doses in Hong Kong, Macau and Taiwan region since launched Vaccination for 5-11 years old was approved in Macau and Taiwan region in April and May 2022; vaccination for 6 months to 4 years old was approved in Taiwan region in August 2022

View entire presentation